Deals and Data

Deals and Data

Thermo Fisher Scientific acquires Advanced Scientifics; leverages global reach to bring innovative bioprocessing solutions to larger customer base. (GEN News, 02/05/15)

Pfizer to acquire Hospira to expand potential for growth in injectable drugs, infusion technologies, and biosimilars. (GEN News, 02/05/15)

EU expands Janssen’s label on multiple myeloma drug Velcade to cover mantle cell lymphoma. (PharmaTimes, 02/07/15)

GlaxoSmithKline seeks EMA approval for additional indication for Revolade to treat pediatric patients aged one year and above with chronic immune thrombocytopenic purpura. (PBR, 02/09/15)

GlaxoSmithKline and Theravance kick off second global Phase II study to assess a closed triple combination of fluticasone furoate/umeclidinium/vilanterol in patients with chronic obstructive pulmonary disease. (PharmaTimes, 02/09/15)

Pfenex and Hospira team up to develop PF582, a biosimilar candidate to eye treatment Lucentis. (GEN News, 02/10/15)

FDA advisory committee to review Amgen’s talimogene laherparepvec for metastatic melanoma treatment. (Healio, 02/11/15)

Trovagene’s IPO closes; to use net proceeds for R&D, working capital, and other general corporate purposes. (GenomeWeb, 02/11/15)

AbbVie submits NDA for two direct-acting antiviral regiment of paritaprevir/ritonavir with ombitasvir to treat hepatitis C virus infection genotype 1. (Healio, 02/12/15)

Intrexon acquires ActoGeniX; combines the companies’ technologies to create new oral biologic drugs for a variety of disease targets. (GEN News, 02/13/15)

CareFusion collaborates with Apnea Sciences, Breas Medical and Codonics; to distribute products and extend partnership. (MassDevice, 02/15/15)[JJ2]

FDA grants priority review for Novartis’ treatment of patients with HF and reduced ejection fraction. (Healio, 02/15/15)

FDA accepts Pfizer’s NDA for ALO-02, extended release capsules, an abuse-deterrent formulation opioid for pain management. (PBR, 02/16/15)

The Scripps Research Institute’s study shows the immune response to infection can be improved indefinitely; outlines path to making more effective vaccines. (U-T San Diego, 02/16/15)

Monsanto makes highly hybridized seeds available to home gardeners. (Sacramento Business Journal, 02/17/15)

Neurocrine Biosciences begins $225m stock offering to fund research and development and drug commercialization. (U-T San Diego, 02/18/15)

The Scripps Research Institute creates genetically engineered protein that inactivates virtually all strains of HIV. (U-T San Diego, 02/18/15)

« Return to Table of Contents